4.7 Review

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor

期刊

FRONTIERS IN PHARMACOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.772435

关键词

natural products; liver X receptor; farnesoid X receptor; docking; agonists; antagonists

资金

  1. Finance Science and Technology Project of Hainan Province [ZDKJ202018]
  2. Marine Economy Development Project of Guangdong Province [GDNRC2021052]
  3. Key Special Project for Introduced Talents Team of Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou) [GML2019ZD0406]
  4. National Natural Science Foundation of China [U20A20101, 81973235, 81973388, 81673677]
  5. Guangdong Local Innovation Team Program [2019BT02Y262]
  6. K. C. Wong Education Foundation [GJTD-2020-12]

向作者/读者索取更多资源

This review provides an overview of natural products that can influence LXRs and FXR, serving as a reference for future research on novel LXRs and FXR agonists and antagonists, and attracting more professional scholars for in-depth discussions.
Nuclear receptors (NRs) are a superfamily of transcription factors induced by ligands and also function as integrators of hormonal and nutritional signals. Among NRs, the liver X receptors (LXRs) and farnesoid X receptor (FXR) have been of significance as targets for the treatment of metabolic syndrome-related diseases. In recent years, natural products targeting LXRs and FXR have received remarkable interests as a valuable source of novel ligands encompassing diverse chemical structures and bioactive properties. This review aims to survey natural products, originating from terrestrial plants and microorganisms, marine organisms, and marine-derived microorganisms, which could influence LXRs and FXR. In the recent two decades (2000-2020), 261 natural products were discovered from natural resources such as LXRs/FXR modulators, 109 agonists and 38 antagonists targeting LXRs, and 72 agonists and 55 antagonists targeting FXR. The docking evaluation of desired natural products targeted LXRs/FXR is finally discussed. This comprehensive overview will provide a reference for future study of novel LXRs and FXR agonists and antagonists to target human diseases, and attract an increasing number of professional scholars majoring in pharmacy and biology with more in-depth discussion.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据